OSspray raises £200k from angel investors

OSspray Limited, the emerging regenerative dentistry company based at King’s College London Dental School, is pleased to announce that is has raised £200k from a syndicate of angel investors. This brings the total raised since the Company was founded to over £500k.
OSspray develops innovative bioactive powders for use as teeth cleaning, desensitising and whitening agents. The OSspray powders will compete in the air polishing segment of the preventative dentistry market, a $70bn market growing at c10% per annum. The OSspray powders can be used in all incumbent air polishing equipment and aim to provide the dentist and hygienist with a novel treatment that significantly improves tooth cleaning whilst also whitening and desensitising patients’ teeth. Additionally the time of treatment is dramatically reduced thereby enabling greater patient throughput within dental practices.
An application for FDA approval for the Company’s first product, a cleaning and desensitising powder, has been submitted and clearance to market is expected before the end of the year. The funds raised in this round will be used to secure the appointment of a full time CEO and complete user acceptability testing prior to product launch during 2007.
The Company is also pleased to announce the appointment of Michael Crane as a non-executive director. Michael has had a distinguished career in the dental industry, most recently as a main Board Director of Dentsply International, the largest professional dental products company in the world. Michael’s experience and industry contacts will be key to OSspray’s successful market entry.
Commenting on the investment, Simon Cartmell, Chairman of OSspray, said:
“This is a very exciting time for OSspray as we move towards first revenues in the coming year and we see a great opportunity for OSspray’s products as the focus in dentistry shifts from functional preservation and repair towards prevention and aesthetics. I am delighted to welcome our new investors into the Company and would like to thanks our existing major investors, in particular Kinetique Biomedical Seed Fund, for their continued support”.

SEARCH Press Releases :